PEG-TNF

Drug Profile

PEG-TNF

Alternative Names: PEG-tumour necrosis factor; PEGylated TNF; Pegylated tumour necrosis factor; Polyethylene glycol-bound TNF

Latest Information Update: 04 Apr 2003

Price : $50

At a glance

  • Originator National Institute of Bioscience and Human-Technology
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Apr 2003 No development reported - Preclinical for Cancer in Japan (unspecified route)
  • 08 Aug 2001 A preclinical study has been added to the Cancer pharmacokinetics section
  • 03 Jul 2000 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top